Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells
Authors
Keywords
Ovarian cancer, Apatinib, Glucose metabolism, VEGFR2, SOX5
Journal
CELLULAR ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-20
DOI
10.1007/s13402-019-00455-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer
- (2018) Xi Cheng et al. CANCER LETTERS
- A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
- (2018) Mingming Miao et al. GYNECOLOGIC ONCOLOGY
- Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target
- (2018) Gustav van Niekerk et al. CELLULAR ONCOLOGY
- Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
- (2018) Chun-Yan Lan et al. LANCET ONCOLOGY
- Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer
- (2017) Anna Markowska et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Successful treatment of ovarian cancer with apatinib combined with chemotherapy
- (2017) Mingzi Zhang et al. MEDICINE
- Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
- (2017) Linghui Deng et al. OncoTargets and Therapy
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
- (2017) Kuisheng Liu et al. Cell Death & Disease
- Sox5 regulates beta-cell phenotype and is reduced in type 2 diabetes
- (2017) A. S. Axelsson et al. Nature Communications
- Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
- (2016) Giandomenico Roviello et al. CANCER LETTERS
- Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials
- (2016) Fei Shan et al. CANCER LETTERS
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer
- (2016) Khalid El Bairi et al. CELLULAR ONCOLOGY
- MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5
- (2015) Wang Renjie et al. CANCER LETTERS
- Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
- (2014) Xichun Hu et al. BMC CANCER
- Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype
- (2014) B Bhattacharya et al. BRITISH JOURNAL OF PHARMACOLOGY
- Apatinib for the treatment of gastric cancer
- (2014) Ruixuan Geng et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism
- (2014) Jun-gang Zhao et al. TUMOR BIOLOGY
- Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling
- (2013) B N Prashanth Kumar et al. BMC CANCER
- Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
- (2013) Sampurna Chatterjee et al. JOURNAL OF CLINICAL INVESTIGATION
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer
- (2013) Ting-Yan Shi et al. MEDICAL ONCOLOGY
- Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells
- (2011) Xiu-zhen Tong et al. BIOCHEMICAL PHARMACOLOGY
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
- (2010) Y.-j. Mi et al. CANCER RESEARCH
- Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer
- (2010) Tomomi Egawa-Takata et al. CANCER SCIENCE
- Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence
- (2009) E Tchougounova et al. ONCOGENE
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Functional significance of VEGFR-2 on ovarian cancer cells
- (2008) Whitney A. Spannuth et al. INTERNATIONAL JOURNAL OF CANCER
- An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
- (2008) R. Aesoy et al. MOLECULAR CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search